MedTrace Logo

Risk Factors for Poor Tolerance of Ureteral Double-J Stent

NCT06815107 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-02-07

No results posted yet for this study

Summary

The placement of a Ureteral Double-J Stent as an emergency treatment or preparation for endoscopy after Colic nephritis is very frequent. It is often poorly supported, most often by young patients. A rich symptomatology is related to the probe responsible for a limitation of activities that can have a strong socio-economic impact. The objective of this study is the identification of the predictive factors of poor tolerance.

Conditions

  • Tolerance
  • Ureteral Double-J Stent
  • Urinary Symptoms

Interventions

OTHER

questionnary

On day 1 of an ureteral double J stenting, each participant will receive the first USSQ questionnaire, in the French validated version. This questionnaire will be completed at home, one week after the intervention and returned at the following consultation or hospitalization.

OTHER

USSQ survey

if the stent is removed less than 6 months later, the second USSQ survey, in the French validated version will be given to the patient when removing the stent. This questionnaire will be completed at home one week after removal of the stent and return to the referent hospital. If the patient does not return the second questionnaire, our team may contact them by phone to complete it.

Sponsors & Collaborators

  • Centre Hospitalier d'Abbeville

    collaborator OTHER

  • centre hospitalier de Compiegne

    collaborator UNKNOWN

  • University Hospital, Caen

    collaborator OTHER

  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2021-04-15
Completion
2026-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06815107 on ClinicalTrials.gov